Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος:	Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial.
Συγγραφείς:	Weiss A; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Division of Breast Surgery, Department of Surgery (Weiss, Nakhlis, Dominici, King, Mittendorf)., Li T; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Department of Data Science (Li, Tayob)., Desai NV; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston MA (Desai, Tung)., Tung NM; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston MA (Desai, Tung)., Poorvu PD; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Department of Medical Oncology (Poorvu, Partridge, Sinclair, Faggen, Constantine, Krop, Tolaney, Winer, Waks) Dana-Farber Cancer Institute, Boston MA., Partridge AH; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Department of Medical Oncology (Poorvu, Partridge, Sinclair, Faggen, Constantine, Krop, Tolaney, Winer, Waks) Dana-Farber Cancer Institute, Boston MA., Nakhlis F; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Division of Breast Surgery, Department of Surgery (Weiss, Nakhlis, Dominici, King, Mittendorf)., Dominici L; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Division of Breast Surgery, Department of Surgery (Weiss, Nakhlis, Dominici, King, Mittendorf)., Sinclair N; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Department of Medical Oncology (Poorvu, Partridge, Sinclair, Faggen, Constantine, Krop, Tolaney, Winer, Waks) Dana-Farber Cancer Institute, Boston MA., Spring LM; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Division of Hematology-Oncology, Massachusetts General Hospital, Boston MA (Spring)., Faggen M; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Department of Medical Oncology (Poorvu, Partridge, Sinclair, Faggen, Constantine, Krop, Tolaney, Winer, Waks) Dana-Farber Cancer Institute, Boston MA., Constantine M; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Department of Medical Oncology (Poorvu, Partridge, Sinclair, Faggen, Constantine, Krop, Tolaney, Winer, Waks) Dana-Farber Cancer Institute, Boston MA., Krop IE; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Department of Medical Oncology (Poorvu, Partridge, Sinclair, Faggen, Constantine, Krop, Tolaney, Winer, Waks) Dana-Farber Cancer Institute, Boston MA., DeMeo M; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks)., Wrabel E; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks)., Alberti J; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks)., Chikarmane S; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Department of Radiology (Chikarmane), Brigham and Women's Hospital, Boston MA., Tayob N; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Department of Data Science (Li, Tayob)., King TA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Division of Breast Surgery, Department of Surgery (Weiss, Nakhlis, Dominici, King, Mittendorf)., Tolaney SM; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Department of Medical Oncology (Poorvu, Partridge, Sinclair, Faggen, Constantine, Krop, Tolaney, Winer, Waks) Dana-Farber Cancer Institute, Boston MA., Winer EP; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Department of Medical Oncology (Poorvu, Partridge, Sinclair, Faggen, Constantine, Krop, Tolaney, Winer, Waks) Dana-Farber Cancer Institute, Boston MA., Mittendorf EA; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Division of Breast Surgery, Department of Surgery (Weiss, Nakhlis, Dominici, King, Mittendorf)., Waks AG; From the Harvard Medical School, Boston MA (Weiss, Li, Desai, Tung, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, Chikarmane, Tayob, Fing, Tolaney, Winer, Mittendorf, Waks).; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston MA (Weiss, Poorvu, Partridge, Nakhlis, Dominici, Sinclair, Spring, Faggen, Constantine, Krop, DeMeo, Wrabel, Alberti, Chikarmane, King, Tolaney, Winer, Mittendorf, Waks).; Department of Medical Oncology (Poorvu, Partridge, Sinclair, Faggen, Constantine, Krop, Tolaney, Winer, Waks) Dana-Farber Cancer Institute, Boston MA.
Πηγή:	Journal of the American College of Surgeons [J Am Coll Surg] 2023 Aug 01; Vol. 237 (2), pp. 247-256. Date of Electronic Publication: 2023 May 17.
Τύπος έκδοσης:	Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
Γλώσσα:	English
Στοιχεία περιοδικού:	Publisher: Lippincott Williams & Wilkins, Inc Country of Publication: United States NLM ID: 9431305 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-1190 (Electronic) Linking ISSN: 10727515 NLM ISO Abbreviation: J Am Coll Surg Subsets: MEDLINE
Imprint Name(s):	Publication: 2022- : [Baltimore, MD] : Lippincott Williams & Wilkins, Inc. Original Publication: Chicago, Ill. : The College, c1994-
Ιατρικοί όροι (MeSH):	Breast Neoplasms/drug therapy , Breast Neoplasms/pathology, Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Paclitaxel/therapeutic use ; Erb-b2 Receptor Tyrosine Kinases/therapeutic use ; Trastuzumab/therapeutic use ; Female ; Humans ; Neoadjuvant Therapy ; Prospective Studies ; Antibodies, Monoclonal, Humanized
Περίληψη:	Background: The impact of abbreviated neoadjuvant regimens for HER2+ breast cancer on rates of breast conservation therapy (BCT) is unclear. We aimed to determine BCT rates in a single-arm prospective trial of neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) in patients with stage II or III HER2+ breast cancer. Study Design: BCT eligibility was prospectively recorded before and after THP. Pre- and posttreatment mammogram and breast ultrasound were required; breast MRI was encouraged. Patients with a large tumor to breast size ratio were eligible for downsizing. Multifocal/multicentric tumors, extensive calcifications, and contraindications to radiation were considered BCT contraindications. Results: Overall, 92 patients who received neoadjuvant THP on trial were included. At presentation, 39 (42.4%) were considered eligible for BCT and 53 (57.6%) were not. BCT-eligible patients were older (median 54 vs 47 years, respectively; p = 0.006) and had smaller tumors by palpation (median 2.5 vs 3 cm, respectively; p = 0.004). Of 53 BCT-ineligible patients, 28 were candidates for tumor downsizing, whereas 25 had contraindications to BCT. Overall, 51 (55.4%) patients underwent BCT. Of the 28 patients who were candidates for downsizing, 22 (78.6%) became BCT-eligible after THP and 18 of 22 (81.8%) underwent BCT. In total, 44 of 92 (47.8%) patients experienced breast pathologic complete response (ypT0), including 11 of 25 (44.0%) patients with BCT contraindications at presentation. Conclusions: De-escalated neoadjuvant systemic therapy led to high BCT rates in this cohort. The impact of de-escalated systemic therapy on local therapy and outcomes in early stage HER2+ breast cancer warrants further investigation. (Copyright © 2023 by the American College of Surgeons. Published by Wolters Kluwer Health, Inc. All rights reserved.)
Σχόλια:	Comment in: J Am Coll Surg. 2023 Aug 1;237(2):256-258. doi: 10.1097/XCS.0000000000000719.. (PMID: 37199440)
References:	van Nes JG, Putter H, Julien JP, et al.; Cooperating Investigators of the EORTC. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. Breast Cancer Res Treat. 2009;115:101–113. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15:2483–2493. von Minckwitz G, Huang CS, Mano MS, et al.; KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–628. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25–32. Nitz U, Gluz O, Graeser M, et al.; WSG-ADAPT investigators. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2022;23:625–635. Bellon JR, Guo H, Barry WT, et al. Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Res Treat. 2019;176:303–310. O’Sullivan CC, Ballman KV, McCall L, et al. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncol. 2021;17:4665–4676. Golshan M, Cirrincione CT, Sikov WM, et al.; Alliance for Clinical Trials in Oncology. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Res Treat. 2016;160:297–304. Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018;19:115–126. Waks AG, Desai NV, Li T, et al. A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. NPJ Breast Cancer. 2022;8:63. Laws A, Hughes ME, Hu J, et al. Impact of residual nodal disease burden on technical outcomes of sentinel lymph node biopsy for node-positive (cN1) breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2019;26:3846–3855. Weiss A, King C, Grossmith S, et al. How often does retrieval of a clipped lymph node change adjuvant therapy recommendations? a prospective, consecutive, patient cohort study. Ann Surg Oncol. 2022;29:3764–3771. Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105–2122. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–2795. Semiglazov V, Eiermann W, Zambetti M, et al. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study. Eur J Surg Oncol. 2011;37:856–863. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24:2278–2284. Criscitiello C, Azim HA Jr, Agbor-tarh D, et al. Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. Ann Oncol. 2013;24:1980–1985. Groen EJ, van der Noordaa MEM, Schaapveld M, et al. Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer. Breast Cancer Res Treat. 2021;189:213–224. Blair S, McElroy M, Middleton MS, et al. The efficacy of breast MRI in predicting breast conservation therapy. J Surg Oncol. 2006;94:220–225. Bae SJ, Ahn SG, Yoon CI, et al. Measuring tumor extent based on subtypes using magnetic resonance imaging: radiologic-pathologic discordance and high positive margin rates in breast cancer. J Breast Cancer. 2019;22:453–463. Fujii T, Kogawa T, Wu J, et al. Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Br J Cancer. 2017;116:509–514. Petruolo O, Sevilimedu V, Montagna G, et al. How often does modern neoadjuvant chemotherapy downstage patients to breast-conserving surgery? Ann Surg Oncol. 2021;28:287–294. Sun S, van la Parra RFD, Rauch GM, et al. Patient selection for clinical trials eliminating surgery for HER2-positive breast cancer treated with neoadjuvant systemic therapy. Ann Surg Oncol. 2019;26:3071–3079. Criscitiello C, Golshan M, Barry WT, et al. Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: a meta-analysis. Eur J Cancer. 2018;97:1–6. Boughey JC, Rosenkranz KM, Ballman K, et al. Impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral breast cancer – results from alliance Z11102 [abstract]. Presented at the San Antonio Breast Cancer Symposium. 2022. von Minckwitz G, Darb-Esfahani S, Loibl S, et al. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat. 2012;132:863–870. Weiss A, Lee KC, Romero Y, et al. Calcifications on mammogram do not correlate with tumor size after neoadjuvant chemotherapy. Ann Surg Oncol. 2014;21:3310–3316. Feliciano Y, Mamtani A, Morrow M, et al. Do calcifications seen on mammography after neoadjuvant chemotherapy for breast cancer always need to be excised? Ann Surg Oncol. 2017;24:1492–1498. Lee J, Park NJ, Park HY, et al. Oncologic necessity for the complete removal of residual microcalcifications after neoadjuvant chemotherapy for breast cancer. Sci Rep. 2022;12:21535.
Molecular Sequence:	ClinicalTrials.gov NCT03716180
Substance Nomenclature:	P88XT4IS4D (Paclitaxel) EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) P188ANX8CK (Trastuzumab) K16AIQ8CTM (pertuzumab) 0 (Antibodies, Monoclonal, Humanized)
Entry Date(s):	Date Created: 20230517 Date Completed: 20230720 Latest Revision: 20260127
Update Code:	20260130
DOI:	10.1097/XCS.0000000000000761
PMID:	37194964
Βάση Δεδομένων:	MEDLINE

View record from ScienceDirect

Full Text Finder

Περιγραφή
ISSN:	1879-1190
DOI:	10.1097/XCS.0000000000000761